Unveiling a Biomarker Signature of Meningioma: the Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis
Author | Halabi, Reem |
Author | Dakroub, Fatima |
Author | Haider, Mohammad Z. |
Author | Patel, Stuti |
Author | Amhaz, Nayef A. |
Author | Reslan, Mohammad A. |
Author | Eid, Ali H. |
Author | Mechref, Yehia |
Author | Darwiche, Nadine |
Author | Kobeissy, Firas H. |
Author | Omeis, Ibrahim |
Author | Shaito, Abdullah |
Available date | 2023-08-29T08:25:03Z |
Publication Date | 2023 |
Identifier | http://dx.doi.org/10.20944/preprints202308.1235.v1 |
Citation | Halabi, R.; Dakroub, F.; Haider, M.Z.; Patel, S.; Amhaz, N.A.; Reslan, M.A.; Eid, A.H.; Mechref, Y.; Darwiche, N.; Kobeissy, F.H.; Omeis, I.; Shaito, A. Unveiling a Biomarker Signature of Meningioma: the Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis . Preprints 2023, 2023081235. https://doi.org/10.20944/preprints202308.1235.v1 |
Abstract | Meningiomas are the most prevalent primary intracranial tumors. The majority are benign but can undergo dedifferentiation in grades classified from I to III. Meningiomas tremendous variability in tumor behavior and slow growth rates complicate their diagnosis and treatment. A deeper comprehension of the molecular pathways and cellular microenvironment factors implicated in meningioma survival and pathology is needed. This review summarizes the known genetic and epigenetic aberrations involved in meningioma, with a focus on Neurofibromatosis type 2 (NF2) and non-NF2 mutations. Novel potential biomarkers for meningioma diagnosis and prognosis are also discussed, including epigenetic-, RNA-, and protein-based markers. Finally, the landscape of available meningioma-specific animal models is overviewed. Use of these animal models can enable planning of adjuvant treatment, potentially assisting in preoperative and postoperative decision-making. Discovery of novel biomarkers will allow more precise meningioma grading, including meningioma identification, subtype determination, and prediction of metastasis, recurrence, and response to therapy. Moreover, these biomarkers may be exploited in the development of personalized targeted therapies that can distinguish between the 15 diverse meningioma subtypes. |
Sponsor | This research is funded by a grant from Morehouse School of Medicine to Firas Kobeissy and a grant from Qatar University to Abdullah A. Shaito. |
Language | en |
Publisher | preprints |
Subject | Meningioma; NF2 mutations; biomarker; miRNA; proteomics |
Type | Preprint |
Files in this item
This item appears in the following Collection(s)
-
Biomedical Research Center Research [709 items ]
-
Medicine Research [1382 items ]